Premium
Short‐term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers
Author(s) -
Júnior José Pedrazzoli,
Pierorsi Marcos de Almeida,
Muscará Marcelo Nicolás,
Dias Heidi Bernadetta,
Ferreira da Silva Claudia Maria,
Mendet Fabiana Duarte,
Nucci Gilberto
Publication year - 1997
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1997.tb00145.x
Subject(s) - sucralfate , diclofenac , bioavailability , oral administration , pharmacokinetics , absorption (acoustics) , potassium , pharmacology , medicine , chemistry , physics , organic chemistry , acoustics
Aims Since patients who regularly take NSAIDS may use sucralfate because of its cytoprotective properties, we examined the influence of this compound on the pharmacokmetics of diclofenac. Methods Potassium diclofenac (105 mg) was administered orally to eighteen healthy male volunteers with or without a 5‐day pre‐treatment with sucralfate (2000 mg twice daily). Blood samples were collected at intervals post‐dose and serum concentrations of diclofenac were determined by reverse‐phase h.p.1.c. Results Pre‐treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h Ml −1 (geometric mean) (range 1815–2827)vs 1821 ng h ml − ’(1295–2562)] and the C max [1135 ng ml −1 (geometric mean) (range 898–1436) vs 701 ng ml −1 (501–981)] with no significant delay in absorption [t max 1.0 h (median) (range 0.5–2.0) vs 1.0 h (0.5‐4.0)l. Conclusions The short‐tern treatment of healthy male volunteers with sucralfate decreases potassium diclofenac bioavailability. These findings suggest that either an appropriate increase in the diclofenac intake or the use of another gastric mucosa protector must be adopted.